In coming decades, a rapidly scaling fertility industry and increased access to IVF therapies will be responsible for nearly 300 million global births - almost all of which will rely upon frozen fertility cells. To meet this rapidly growing demand, TMRW has created the first fully Robotic Process Automation (RPA) platform designed specifically for IVF. Already experiencing rapid market adoption by leading U.S. clinics, TMRW's platform is poised to become the global standard. IVF clinicians have embraced TMRW's platform because it replaces an outdated analog IVF cryo-management function with proven risk-mitigating robotic process automation technology. TMRW's integrated platform provides the world's first complete RFID cryo-temperature compatible digital chain of custody for all fertility cells-including eggs and embryos. TMRW software is constantly vigilant and automates 17,000 daily environmental 'health checks' that ensure the safety, and security of the world's most precious cells.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
05/29/19 | $12,000,000 | Series A |
Dubin & Co. Life Sciences Innovation Fund | undisclosed |